No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to ...

No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion ...

NASARIX achieves positive biological safety resultsShares of Polyrizon Ltd. (NASDAQ:PLRZ) gained 10% on Friday after the ...

The study is enrolling up to 300 US patients with CRS to evaluate the ESSpand DCB with endoscopic sinus surgery.

Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader ...

Now the payment company Stripe, founded by brothers Patrick and John Collison, says it will fund a new $500 million nonprofit ...

ALK has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for EURneffy 1mg, a needle-free adrenaline treatment for children ...

ARS Pharmaceuticals, Inc. shares fell in after-hours trading on Wednesday after the company provided commercial and financial ...

ARS Pharmaceuticals is rated Hold due to heightened near-term execution risk despite a compelling long-term Neffy opportunity ...

Let’s take a look at the winners one more time From trusted hometown businesses and beloved restaurants to outstanding ...

Spread the love“`html Snoring is more than just a nighttime annoyance; it can signal underlying health problems and lead to ...

NYSE: NSRX Lily: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you have joined us. The next ...